Ultragenyx: Q2 Earnings Snapshot
NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $131.6 million in its second quarter.
On a per-share basis, the Novato, California-based company said it had a loss of $1.52.
The results exceeded Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.64 per share.
The biotechnology company posted revenue of $147 million in the period, which also beat Street forecasts. Nine analysts surveyed by Zacks expected $123.4 million.
Ultragenyx expects full-year revenue in the range of $530 million to $550 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE
Candorium Free Members
Join Candorium to access the full article and more